Market Signal Briefing

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

Ethereum has hit a new milestone as its staking has climbed to an all-time high. This trend indicates the investors’ long-term confidence in the token’s potential. Amid this major development, major players like BitMine are expanding their Ethereum staking portfolio, contributing to the growing confidence in the altcoin.

Ethereum Staking Surges, Locks Nearly a Third of ETH Supply According to the latest reports, Ethereum staking has reached a record high, hitting $118 billion in ETH. This points out a drastic increase in long-term holding behavior of ETH investors, as staking now comprises almost a third of the total supply of Ether.

Reports state that the Beacon Chain holds about 35.8 million ETH, constituting 29.5% of Ethereum’s circulating supply. The Beacon Chain is Ethereum’s core proof-of-stake network that manages staking and validators.

The Ethereum staking, marked at $118 billion at the current ETH price of $3,302, marks the largest ratio ever marked for the token. The new value surpasses the former record of 29.54% marked in July 2025. Lido Finance, one of the staking providers, holds around 24% of the total Ether staked.

Besides the major increase in staking, there is also a significant amount of on-chain activity in the network. The number of active validators on the network has surged to an impressive 976,117.

An additional 2.3 million ETH are waiting to be staked, signalling that more investors are showing interest in staking rather than selling their tokens. This indicates that the community is largely optimistic about Ether’s future, which in turn could influence its price movements.

BitMine Adds $514M in ETH as Staking Spree Continues BitMine Immersion, the largest Ethereum Treasury company, is one of the largest contributors to the surging ETH staking. As noted by on-chain analytics platform Lookonchain, BitMine has added another 154,304 ETH to its staking portfolio over the past five hours. This is equivalent to about $514 million at the current price.

Tom Lee(@fundstrat)'s #Bitmine staked another 154,304 $ETH($514M) in the past 5 hours.

In total, #Bitmine has now staked 1,685,088 $ETH($5.62B).https://t.co/P684j5YQaG pic.twitter.com/ActfBRZV2k

— Lookonchain (@lookonchain) January 15, 2026

Recently, Tom Lee’s BitMine introduced its Ethereum staking initiative to manage its $4 billion debt amid ETH’s previous downturn. Since then, the company has continuously allocated a portion of its ETH holdings to staking.

Alongside the staking expansion, BitMine continues to accumulate Ether tokens, strengthening its Ethereum Treasury. As CoinGape noted, BitMine recently bought 24,266 tokens, bringing its total Ether holdings to 4.17 million.

Thus, the treasury company’s continuous ETH staking has significantly contributed to the rising amount of ETH staked. As the company says it will maintain its strategy, Ethereum staking is poised to reach even higher levels.  

Bitcoin remained resilient on Thursday, holding above a key psychological level after a strong rally earlier in the week, even as broader financial markets turned more cautious and momentum across the crypto market began to cool. The world’s largest cryptocurrency traded near $96,200, gaining around 1% in the past 24 hours and roughly 6% over the past seven days, signaling continued strength despite a softer risk environment.

Ether also maintained elevated levels, hovering near $3,300 after posting more modest gains. The second-largest cryptocurrency had surged alongside bitcoin earlier in the week before entering a period of consolidation. Overall, total crypto market capitalization rose nearly 5% to approximately $3.25 trillion, marking its strongest levels in months before upside momentum eased.

Outside the crypto space, global markets showed signs of risk aversion. Oil prices declined for the first time in six sessions after U.S. President Donald Trump indicated that military action against Iran could be delayed, reducing immediate geopolitical tensions. At the same time, precious metals pulled back from record highs, Asian stock markets edged lower, and U.S. stock-index futures slipped as investors rotated away from technology shares.

Despite this mixed macroeconomic backdrop, crypto sentiment improved notably. The crypto market sentiment index climbed to 48, its highest reading since late October, reflecting growing trader confidence after a cautious end to 2025. According to Alex Kuptsikevich, chief market analyst at FxPro, bitcoin’s technical outlook has strengthened, with the asset clearing several key resistance levels and opening a potential path toward the $100,000 to $106,000 range.

However, Thursday’s price action suggested consolidation rather than a renewed breakout. While bitcoin and ether held their gains, performance among major altcoins was uneven. Solana and BNB traded higher, while XRP dropped about 3% and dogecoin fell more than 3%, underperforming the broader crypto market. Such divergence often points to profit-taking and a pause after a rapid rally.

Stablecoins like USDT and USDC remained firmly pegged to the dollar, indicating no signs of market stress or forced selling. With upcoming U.S. economic data unlikely to change expectations for a Federal Reserve rate cut before midyear, investors are closely watching whether bitcoin can continue to hold above $95,000 as equity markets soften. For now, the crypto market appears to be digesting recent gains rather than accelerating into a new leg higher.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Heavy selling pressure emerged after a failed rally attempt, with late-session stabilization showing exhaustion rather than reversal.

James Ding Jan 15, 2026 06:57

Excerpt Bitcoin shows bullish momentum above key moving averages with RSI at 67. Technical analysis suggests BTC could reach $105,000 in February if it breaks $99,543 resistance. BTC Price Pred...

Excerpt Bitcoin shows bullish momentum above key moving averages with RSI at 67. Technical analysis suggests BTC could reach $105,000 in February if it breaks $99,543 resistance.

BTC Price Prediction Summary • Short-term target (1 week): $99,500 • Medium-term forecast (1 month): $102,000-$108,000 range • Bullish breakout level: $99,543 • Critical support: $93,056

What Crypto Analysts Are Saying About Bitcoin While specific analyst predictions are limited in recent days, institutional forecasts remain optimistic for Bitcoin's trajectory. Standard Chartered maintains their ambitious $200,000 BTC target for 2025, while JPMorgan analysts project Bitcoin could rally to $165,000 by year-end, citing undervaluation against gold and increasing inflows into BTC ETFs.

According to on-chain data from major analytics platforms, Bitcoin's current positioning above key moving averages signals continued institutional accumulation patterns that have historically preceded significant price rallies.

BTC Technical Analysis Breakdown Bitcoin's current technical picture presents a compelling bullish setup. Trading at $96,293.68, BTC has established itself firmly above all major short and medium-term moving averages, with the price sitting 5.7% above the 20-period SMA at $91,118.98.

The RSI reading of 67.03 indicates Bitcoin remains in neutral territory with room for further upside before reaching overbought conditions. This suggests the current rally has sustainable momentum without immediate overextension concerns.

Bitcoin's MACD shows bullish momentum with a histogram reading of 0.0000, indicating the recent crossover continues to support upward price action. The Stochastic oscillator readings of %K at 82.91 and %D at 66.33 suggest strong momentum, though approaching levels that warrant caution for short-term pullbacks.

Particularly notable is Bitcoin's position within the Bollinger Bands, with a %B reading of 0.9635 placing it near the upper band at $96,701.72. This positioning typically indicates strong momentum but also suggests potential resistance in the immediate term.

Bitcoin Price Targets: Bull vs Bear Case Bullish Scenario The bullish case for this BTC price prediction centers on Bitcoin breaking through the immediate resistance at $99,543. A decisive move above this level could trigger momentum-driven buying that pushes Bitcoin toward the $105,000-$108,000 range within 30 days.

Technical confirmation would come from a daily close above $99,500 accompanied by volume expansion above the recent 24-hour average of $2.19 billion. The 200-period moving average at $106,000.96 represents a logical target area where some profit-taking could emerge.

Bearish Scenario The bearish scenario for Bitcoin involves a failure to break the strong resistance at $99,543, potentially leading to a retest of lower support levels. The immediate support at $94,674.74 represents the first line of defense, but a breakdown below this level could see Bitcoin test the strong support at $93,055.79.

Risk factors include potential profit-taking near current levels and broader market sentiment shifts. A break below the 20-period SMA at $91,118.98 would signal a more significant correction toward the $88,000-$90,000 range.

Should You Buy BTC? Entry Strategy For traders considering Bitcoin positions, the current technical setup offers defined entry opportunities. Conservative buyers might wait for a pullback to the $94,000-$95,000 range, which would provide better risk-reward positioning while maintaining the bullish structure.

More aggressive traders could consider entries on any dips toward $96,000 with stops below $93,000. This approach offers approximately 3:1 reward-to-risk if targeting the $105,000 level.

Position sizing should account for Bitcoin's daily ATR of $2,385.15, which indicates significant intraday volatility. Risk management becomes crucial given this volatility profile.

Bitcoin Forecast: Key Levels to Watch This Bitcoin forecast hinges on several critical technical levels over the coming weeks. The immediate resistance cluster between $97,918-$99,543 represents the most significant hurdle for continued upside momentum.

A break above these levels would likely accelerate the move toward $105,000, representing approximately 9% upside from current levels. Conversely, failure to break resistance combined with a move below $94,000 would shift the near-term outlook more cautious.

Conclusion Based on current technical analysis, Bitcoin appears positioned for continued upside with a target range of $102,000-$108,000 over the next 30 days. The combination of strong momentum indicators, positioning above key moving averages, and institutional price targets supports this bullish BTC price prediction.

However, traders should monitor the $99,543 resistance level closely, as this represents the key technical hurdle that must be overcome to validate the bullish scenario. Risk management remains essential given Bitcoin's inherent volatility.

This analysis is for educational purposes only and should not be considered financial advice. Cryptocurrency investments carry significant risk, and past performance does not guarantee future results.

Image source: Shutterstock

btc price analysis btc price prediction

Bitcoin has returned to a price range where repeated profit-taking by long-term holders capped rallies last year, though those wallets are now selling more slowly than in 2025.

Journalist

Posted: January 15, 2026

Ethereum’s price has recovered by 14% in 2026, hitting $3,400 for the first time since mid-December before retracing at press time. More than half of the rally was driven on 13 January, following a softer U.S. inflation print and President Donald Trump’s push for Fed interest rate cuts. 

Still, the king of altcoins could offer more gains to investors. This, according to Garret Bullish, the White House whale insider who made millions of dollars shorting Bitcoin in October. 

In his latest analysis report, Bullish projected that ETH could surge to $5,413, citing the Elliot Wave pattern. 

“We believe ETH has re-entered the (5)th wave of the ascending channel that began in April last year. Theoretical targets: target 1: $5,413; aggressive target 2: $7,155.”

Source: Garret Bullish/X

Based on Ethereum’s [ETH] press time value of $3.35k, this would mean a 60% upside for the base case scenario of $ 5.4k, or a 2x move for the aggressive target. 

The White House whale has an over $600 million ETH long position and believes the Fed’s Powell-Trump conflict is bullish for Bitcoin, Ethereum, and the crypto market overall. He recently said, 

“Historically, geopolitical conflicts in the Middle East have coincided with crypto rallies. According to Gemini data: Avg PnL 30 days after conflict: BTC +14%, ETH +27%; Avg PnL 90 days after conflict: BTC +20%, ETH +39%”].”

Put differently, he expects ETH to outperform in Q1. And, he’s not the only mega-ETH bull in 2026. 

Will ETH outperform BTC? Standard Chartered Bank’s latest report projected that ETH could reach $7,500 by 2026 and double to $15k by 2027, with a long-term target of $40k by 2030. 

However, quantum risk is likely to drag down BTC’s upside potential, giving ETH the opportunity to outperform it in 2026, according to DeFi analyst DeFiIgnas. 

Source: X

Interestingly, the ETH/BTC ratio, an indicator that tracks the relative price performance of ETH against BTC, also hinted at such an outlook at press time. 

The 200-day Moving Average (blue line) has been a crucial support after the ratio dropped in H2 2025. It meant BTC outperformed ETH in H2 2025. However, the ratio has steadily risen since December – A sign that ETH strengthened against BTC over the same period. 

A sustained recovery of the ETH/BTC ratio could push ETH higher above $4k. Especially if Q1 2025’s macro landscape and market liquidity improve. 

Source: ETH/BTC, TradingView 

Final Thoughts Ethereum could front a 60% upswing in the next few weeks, according to a White House insider.  ETH has garnered bullish ratings from analysts, including Standard Chartered Bank. 

Monero (XMR) surged to a new all-time high on Wednesday, breaking above the $797 level as investors poured into privacy-focused cryptocurrencies. The rally capped a strong week for XMR, with prices climbing more than 50%, making Monero one of the best-performing assets in the broader crypto market. The sharp move pushed Monero’s market capitalization above $13 billion and briefly placed it among the top 15 cryptocurrencies by market value, while trading volumes spiked as buyers rushed to gain exposure.

The primary catalyst behind Monero’s price explosion is a renewed global focus on financial privacy. Across major economies, regulators are tightening know-your-customer (KYC) and anti-money-laundering (AML) requirements, reducing the ability to transact anonymously on most blockchains. As compliance burdens increase, users seeking privacy are increasingly turning to cryptocurrencies designed to obscure wallet balances, transaction amounts, and sender identities. Monero remains the most established and widely used privacy coin, benefiting directly from this shift in sentiment.

Ironically, regulatory crackdowns have strengthened demand rather than suppressing it. Recent actions, such as Dubai’s financial regulator banning exchanges in the Dubai International Financial Centre from listing or promoting privacy coins, alongside the European Union’s plans to prohibit anonymous crypto accounts and privacy tokens from 2027, have triggered front-running behavior. Many investors are buying privacy assets now in anticipation of more restricted access in the future.

Monero has also gained from capital rotation away from rival privacy coin Zcash. Governance disputes and the exit of Zcash’s core development team weakened confidence in the project, prompting traders to move funds into Monero, which is perceived as more decentralized and resilient. From a technical perspective, XMR’s breakout above long-standing resistance in the $600–$650 range attracted momentum traders and algorithmic funds, amplifying the rally through increased liquidity and social media attention.

While short-term pullbacks are possible after such a rapid ascent, the broader trend remains intact. As governments expand financial surveillance and restrict anonymity, demand for privacy-focused cryptocurrencies continues to rise, positioning Monero as a key beneficiary in the evolving crypto landscape.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Leading high-frequency trading companies and quantitative hedge funds, including DRW, Susquehanna International Group, and Jump Trading, are establishing dedicated teams to focus on prediction markets. This move signals a shift in a sector traditionally dominated by retail speculation, as reported by the Financial Times. These firms are applying quantitative strategies typical to stocks and derivatives to identify mispricing, arbitrage between platforms, and engage in market-making in inefficient venues. Joseph Saluzzi, co-founder of Themis Trading, stated, “The opportunity is not about guessing outcomes. In a market this new, where platforms are still siloed and liquidity is fragmented, arbitrage opportunities are everywhere.”

Institutional interest is increasingly evident through job listings. DRW is hiring traders for a prediction-markets desk with salaries reaching $200,000. Susquehanna is recruiting to “detect incorrect fair values” and pinpoint market inefficiencies. Swiss-based G-20 Advisors seeks quantitative engineers to develop probability models for event contracts. Other firms, including Flow Traders and specialist funds like Kirin, Anti Capital, and Sfermion, are also expanding their presence in these markets, indicating a broader influx of quant capital.

The surge in institutional interest is supported by rapidly increasing trading activity. Prediction-market platforms have seen volumes rise from less than $100 million monthly in early 2024 to over $8 billion in December 2025. This growth has transformed the niche space into a market attracting professional arbitrageurs.

The structure of major platforms has also attracted sophisticated traders. Susquehanna became the first official market maker on Kalshi, benefiting from reduced fees and higher position limits in exchange for providing liquidity. Such arrangements, common in traditional derivatives markets, underscore the integration of institutional firms within the sector’s infrastructure.

Beyond arbitrage, prediction markets offer specific hedging tools. Boaz Weinstein, founder of Saba Capital Management, described event contracts as enabling portfolio managers to offset discrete outcome probabilities, allowing them to take larger positions elsewhere more confidently.

Nonetheless, some large hedge funds remain cautious, citing the market’s modest size compared to multi-trillion-dollar asset classes and an evolving regulatory landscape. Despite this, the involvement of top-tier trading firms marks a pivotal shift. These firms approach prediction markets not as betting venues but as emerging asset classes characterized by inefficiency and fragmentation, conditions historically favorable for quantitative strategies.

As professional market makers and arbitrageurs enter the space, prediction markets are beginning to mirror early-stage financial markets elsewhere: volatile, imperfect, and increasingly shaped by institutional capital imposing order, liquidity, and price discipline. This evolution suggests the sector’s potential to develop into a significant part of the financial landscape.

Exchange-traded funds (ETFs) are one way investors gain exposure to such markets. ETFs are investment funds traded on stock exchanges, comprising various assets. A ‘spot’ ETF involves direct ownership of the underlying asset, unlike futures-based products. Issuers typically file for ETFs to offer investors diversified exposure with ease of trading and transparency.

Regulatory considerations are crucial as regulators focus on aspects such as custody, market integrity, and investor protection. The approval process for financial products often involves rigorous reviews to ensure compliance with these standards, emphasizing the importance of robust market oversight.

The institutional interest in crypto products by large banks and asset managers is driven by client demand for diversified investment options and the potential for fee-based revenue streams. As the largest cryptocurrency by market value, Bitcoin represents a significant focus in this area, offering a gateway for traditional financial institutions into the digital asset space.

However, prediction markets carry risks. Volatility, liquidity conditions, and operational challenges are inherent. Regulatory uncertainty also poses a risk, as evolving rules could impact market dynamics and participant strategies.

Competition in prediction markets is intense, with multiple issuers often filing similar products. Timelines for regulatory approval can be uncertain, and product amendments are common as issuers adapt to changing market conditions.

Looking ahead, the prediction market sector may see further developments as regulatory reviews continue and institutional participation increases. Stakeholders will closely monitor potential amendments, requests for comment, and regulatory decisions that could shape the future of this evolving market.

Post Views: 1

Eric Adams Rejects “Rug Pull” Claims Tied to NYC Token Despite Big Losses

Amin Ayan

Crypto Journalist

Amin Ayan

Part of the Team Since

Apr 2025

About Author

Amin Ayan is a crypto journalist with over four years of experience in the industry. He has contributed to leading publications such as Cryptonews, Investing.com, 99Bitcoins, and 24/7 Wall St. He has...

Has Also Written

Last updated: 

8 minutes ago

Former New York City Mayor Eric Adams has rejected allegations that his newly launched meme coin, NYC Token, was linked to suspicious liquidity withdrawals that left investors facing heavy losses.

Key Takeaways:

Eric Adams denies moving funds, blaming NYC Token losses on early market volatility. The project admits to temporary liquidity rebalancing during the launch. Onchain data flagged large withdrawals, sustaining rug pull concerns. In a statement posted Tuesday to Adams’ X account, spokesperson Todd Shapiro said reports suggesting Adams moved money out of the NYC Token were “false and unsupported by any evidence.”

The statement added that Adams neither touched investor funds nor profited from the token’s launch, insisting that “no funds were removed from the NYC Token.”

NYC Token Team Blames Early Volatility for Post-Launch Price DropShapiro characterized the token’s sharp price swings as a familiar feature of early-stage crypto projects.

“Like many newly launched digital assets, the NYC Token experienced market volatility,” he said, framing the turbulence as a market-driven event rather than a coordinated withdrawal.

The response followed heightened scrutiny of onchain activity surrounding NYC Token, which suffered a steep drawdown shortly after launch.

The project itself acknowledged liquidity adjustments, saying it had to “rebalance” amid strong demand.

In a post on X, the team said its partners temporarily removed funds for time-weighted average price execution and later added additional capital back into the liquidity pool.

Those explanations have done little to calm critics. Independent analysts flagged transactions that appeared to drain liquidity near peak prices, triggering concerns among traders.

One of the earliest warnings came from Rune Crypto, which alleged that roughly $3.4 million in liquidity was withdrawn shortly after launch and accused the project of operating like a rug pull.

Onchain visualization platform Bubblemaps also highlighted unusual patterns.

According to its analysis, a wallet connected to the token deployer removed around $2.5 million in USDC near the market top and later added back approximately $1.5 million after the token’s price had fallen more than 60%.

Bubblemaps: 60% of NYC Token Traders Lost Money After LaunchBubblemaps further detailed the scope of trader losses. Of roughly 4,300 participants, an estimated 60% ended the token’s first hours in the red.

Most losses were under $1,000, but about 200 traders lost between $1,000 and $10,000. A smaller group suffered losses in the tens of thousands, while at least fifteen traders lost more than $100,000.

https://twitter.com/bubblemaps/status/2011465515148218478?s=20

Adams’ camp has emphasized that the NYC Token was pitched as a vehicle to support nonprofit initiatives and community education, not as a speculative investment.

Still, the episode has fueled transparency concerns, particularly around governance and liquidity management.

The project’s website states that the token is deployed on Solana with a total supply of one billion tokens, 70% of which are allocated to a reserve excluded from circulating supply.

While the team has cited unnamed partners in its liquidity actions, it has yet to publish a detailed breakdown, leaving questions about oversight and accountability unresolved.

Bitcoin (BTC) price is back in motion after a tight consolidation phase by pushing higher even as the broader market remains cautious. Typically, a breakout invites optimism. This time, the reaction looks different: sentiment indicators suggest traders are still hesitant to trust the move, and social commentary is skewing more negative despite the upside.

That mismatch, price rising while conviction lags, is often where rallies can surprise. When the crowd stays fearful, it leaves room for sidelined capital to re-enter and for short positioning to unwind, both of which can add fuel to continuation. With BTC now holding above its previous range, the focus shifts to whether disbelief fades or whether it powers the next leg toward the $100K psychological mark.

Traders Stay Skeptical Even as Bitcoin Breaks OutIn strong trends, price often moves first and sentiment follows later. Right now, Bitcoin is showing that classic disconnect: it’s pushing higher after breaking out of consolidation, yet the crowd still looks unconvinced. Santiment’s positive vs. negative commentary ratio underscores this shift, dropping into the fear zone even as BTC trends upward on the price line. 

That combination typically signals a “disbelief rally,” where traders hesitate to chase, shorts remain active, and sidelined capital waits for a pullback that may not come. Ironically, that caution can help extend upside because the market isn’t overcrowded with euphoric longs. The key is follow-through: if BTC holds above the breakout range, this pessimism can act as fuel, keeping the $100K psychological level firmly in focus.

Bitcoin Price Outlook: Can Sentiment Fuel a Run Toward $100K?With BTC holding above its former consolidation band, the next phase depends on whether buyers can defend the breakout while sentiment stays cautious. When disbelief lingers, rallies often grind higher because dips get bought and bearish bets unwind in waves. A steady push toward $100K becomes more likely if Bitcoin price keeps printing higher highs and higher lows and avoids slipping back into the previous range.

That said, the risk is straightforward: if BTC loses the breakout level and sentiment remains fearful, the market can interpret it as a failed move, triggering profit-taking and a deeper pullback. For bulls, the cleanest confirmation would be continued closes above the prior range, followed by a successful retest. For now, Santiment’s fear-zone reading suggests the rally isn’t overcrowded, which can keep upside momentum intact—provided price structure doesn’t break.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

The cryptocurrency market continues its excellent start to the week, with Bitcoin approaching a key psychological level after adding nearly 2% to its value in the last 24 hours.

The leading cryptocurrency briefly touched the $98k level but has slightly retraced towards the $96k level at press time.

The positive performance comes amid improved risk appetite fueled by softer-than-expected US inflation data on Tuesday.

The resumption of massive inflows into spot Bitcoin ETFs also suggests that institutions are now adding more positions into the market. 

Macroeconomic data boosts risk appetite Copy link to section

The cryptocurrency market has performed well over the past few days, with Bitcoin, Ether, and XRP recording massive gains during that period.

On Tuesday, the US Bureau of Labor Statistics (BLS) released data on Tuesday showing that the US Consumer Price Index (CPI) rose 2.7% YoY in December.

The headline and core CPI rose by 0.3% and 0.2%, respectively, on a monthly basis. This was followed by the Producer Price Index (PPI) data on Wednesday, which rose 3%, higher than expected. 

These data increase the odds of the Federal Reserve cutting interest rates this year, resulting in Bitcoin’s price rallying to $98k on Wednesday. 

In addition to that, institutional demand for Bitcoin products has resumed strongly.

CoinGlass data revealed that Bitcoin spot ETFs recorded inflows of $854 million on Wednesday, the highest single-day inflow since October 6. 

If this inflow continues, BTC could extend its ongoing rally. The current macroeconomic conditions favor further inflow by institutional investors.

Is Bitcoin heading towards $100k? Copy link to section

The BTC/USD 4H Chart is bullish and efficient as Bitcoin is currently trading above $96k.

The technical indicators are bullish, suggesting that Bitcoin could rally higher in the near term.

The Moving Average Convergence Divergence (MACD) indicator on the 4-hour chart remains in a buy signal triggered three weeks ago, suggesting that bullish momentum could expand further.

The Relative Strength Index (RSI) of 68 also shows that BTC is not yet in the overbought territory, suggesting there is further bullish expansion on the horizon.

A close of the daily candle above the 100-day Exponential Moving Average (EMA) at $95,987 would confirm BTC’s short-term bullish outlook. 

If the bullish trend continues, BTC could rally toward the key psychological $100,000 level. The bulls will likely face resistance at the 200-day EMA price of $99,581. 

On the other hand, if the market undergoes a correction after its recent expansion, BTC could extend the decline toward the key support at $94,253 and the 50-day Exponential Moving Average (EMA) at $91,858.

Currently, the market conditions are bullish, with technical indicators supporting further upward expansion. The retracements encountered could be pullbacks before Bitcoin races on to new resistance levels. 

Journalist

Posted: January 15, 2026

ASTER retraced by 5%. This pullback came after its 10% rally that reflected the broader crypto market recovery.

The altcoin started its run after MYX Finance’s bull run, which piqued interest in this sector following a period of inactivity. A Binance partnership further boosted its price.

Per Satoshi Club on X, ASTER jumped over 6% upon the announcement.

This meant increased trading activity of the token alongside a volume surge. Apart from increased trading activity, there was the risk of overleveraging, as this could affect the sustainability of trends.

On-chain activity driving price action On the chain activity side, the data from Nansen AI supported this bullish charge. To begin with, five active wallets of the top PnL traders showed net inflows of more than $70K over the past seven days.

Additionally, fresh wallets accumulated over $685K in capital during the past week. However, some public figures were selling, though their $24K capital was not enough to shake the uptrend.

More data showed that exchange outflows, which are bullish in nature, were spiking up. These net outflows exceeded $3.1 million, indicating accumulation.

Source: Nansen AI

Additionally, the number of holders was on the rise over the past month. Interestingly, since the 5th of January, holders rose from 200K to 206.63K as of press time.

Source: CoinMarketCap

The market cap also spiked to $1.94 billion following a period of inconsistency since the end of 2025.

While the metrics showed the potential to rise further, the price action was on the rise. Will it sustain staying above the breakout zone?

On the charts, ASTER broke out from a massive falling wedge pattern and seemed to have completed the retest. This after the pullback that followed the breakout equaled the low around $0.67.

The On Balance Volume (OBV) was at $200 million, suggesting massive trading.

The Chaikin Money Flow (CMF) was above the neutral, indicating capital was being pumped into the token, especially with the Binance partnership on leveraged trading.

Source: TradingView

Staying above the breakout zone could open the door for a rally in excess of 120% over the next few sessions. This was according to a prediction post by Captain Faibik on X.

If the prediction comes to pass, ASTER could cross the $1 milestone soon.

Final Thoughts ASTER rallies after a Binance partnership and chain activity growth.  To rally 120%, ASTER needs to stay above the falling wedge pattern.

ASTER is trading near a key resistance zone after a sharp rise in activity, with price compressing just below levels that previously capped upside.

Summary

Aster price is approaching $0.76 resistance following the launch of perpetual futures on Binance Wallet. Trading volume jumped 45%, and futures open interest rose, indicating new market positions. Key support sits near $0.72, while a breakout above $0.76 could target $0.78–$0.80. At press time, ASTER was changing hands at around $0.7402, down 1.5% on the day. Over the past week, the price has moved within a $0.6847 to $0.7736 range, while the token is still down about 10% over the last 30 days.

Trading activity has increased significantly despite the muted daily move. Aster’s (ASTER) 24-hour trading volume rose 45% to $378 million, indicating renewed interest.

Derivatives data shows a similar trend. Futures volume jumped 46% to $816 million while open interest rose 2.15% to $454 million, as per CoinGlass data. This mix suggests fresh positions are entering the market rather than traders simply rotating existing exposure.

Binance Wallet launches Aster perpetuals The increase in activity coincides with Aster’s Jan. 14 launch of perpetual futures trading via Binance Wallet. With leverage of up to 100x, the integration enables users to trade on-chain perps straight from self-custody wallets, beginning on BNB Smart Chain.

Additionally, Aster and Binance Wallet also rolled out an on-chain perps campaign with rewards of up to 200,000 USDT to support the launch. Trades made via Binance Wallet earn Aster points, which will count in ongoing incentive campaigns, competitions, and rewards programs.

Aster now powers perpetuals on @BinanceWallet (Web).

SafePal. Trust Wallet. Now Binance Wallet.

When wallets need perps infrastructure: matching engines, deep liquidity, precise pricing—they no longer reinvent the wheel.

Aster is where wallets go for perps.

👉… https://t.co/CXUjNyOUTG

— Aster (@Aster_DEX) January 14, 2026 This marks Aster’s latest wallet integration following similar rollouts with Trust Wallet and SafePal, strengthening its position as a perps backend for wallet-based trading.

Looking past the perp launch, there’s a lot more on the horizon. Aster’s layer-1 testnet is currently operational, and the team plans to launch the mainnet during the first quarter of 2026. 

ASTER staking, which is planned for Q2, will introduce on-chain governance. In the meantime, trading competitions and ongoing airdrop campaigns are drawing new users and boosting network activity.

Aster price technical analysis After a strong move, ASTER is currently in a consolidation phase The price recently rose from the $0.69 region into the $0.78–$0.79 region before retreating into a narrow range.

Aster daily chart. Credit: crypto.news The former breakout area around $0.72–$0.73 is holding as support. This zone aligns with the lower Bollinger Band and prior consolidation, making it a key level for structure. The short-term setup is constructive as long as the price stays above it. 

After widening during the rally, Bollinger Bands are starting to shrink. The price is currently rotating around the mid-band, which is close to $0.74, while the upper band is near $0.76. This type of compression often precedes a volatility expansion rather than a slow drift.

Momentum indicators reflect cooling, not weakness. The relative strength index has reset from overbought levels back toward neutral, a common pattern after an impulse move. Candles are getting smaller, and upper wicks near $0.78–$0.80 show sellers defending that zone, but without strong follow-through.

A clean break and hold above $0.76 would put the $0.78–$0.80 supply zone back in play. On the downside, losing $0.72 would likely open a move toward $0.70, where the last major support sits.

Protara Therapeutics, Inc. (TARA) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 6:45 PM EST

Company Participants

Jesse Shefferman - Co-founder, CEO, President & Director

Presentation

Unknown Analyst

Welcome, everyone. My name is [ Tai Pavumi ], and I'm welcoming you to the 44th JPMorgan Healthcare Conference. Our next presenting company is Protara Therapeutics. Protara is a clinical stage biotechnology company that's developing transformative therapies for people with rare cancer diseases. And presenting today is CEO, Jesse Shefferman. Please help me welcoming to the stage.

Jesse Shefferman
Co-founder, CEO, President & Director

Thank you. Thanks, [ Tai ]. Thank you to the JPMorgan team for having us. I'm looking forward to talking through the Protara story. Quick forward-looking statements. So as [ Tai ] 1said, Protara is a clinical stage company focused on oncology and in rare disease. In oncology, our primary focus is in non-muscle invasive bladder cancer, where we have 2 programs in late-stage development, 2 registrational studies in BCG-Unresponsive patients and in BCG-Naïve patients.

On the rare disease side, we have 2 products in clinical development. IV Choline Chloride is a phospholipid substrate replacement therapy for patients that are on parenteral support. That program is in Phase III with a PK-based endpoint. And we also have our lymphatic malformations program, TARA-002 for macrocystic and macrocystic-dominant mixed cystic lesions.

Just gives a sense of our portfolio. For a company of our size, we have a lot of ambition, and this is represented by the various programs that we have in late-stage development. In non-muscle invasive bladder cancer, our ADVANCED-2 study is a single-arm open-label study looking at BCG-Unresponsive patients with carcinoma in situ. There, we are significantly well enrolled in a registrational study that we anticipate will complete enrollment before the end of 2026.

We also

Entrada Therapeutics, Inc. (TRDA) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 6:45 PM EST

Company Participants

Dipal Doshi - CEO & Director

Conference Call Participants

Susmita Roy

Presentation

Susmita Roy

Good afternoon, everyone. My name is Susmita Roy. I'm an associate on the health care investment banking team here at JPMorgan. On behalf of JPMorgan, first of all, welcome. Thank you so much for taking the time to attend the conference. It's been a great conference so far. And to continue the festivities rolling, I'm thrilled to introduce Entrada Therapeutics for their company presentation today.

A little bit about Entrada before we get started. Entrada is focused on treating devastating diseases with intracellular targets. Last week, Entrada highlighted an important progress across its EEV portfolio for neuromuscular and ocular diseases. The company is advancing multiple clinical programs in people living with Duchenne muscular dystrophy in the U.K., EU and the U.S. In 2026, Entrada expects to have 4 clinical stage programs in its DMD franchise, complementing the ongoing clinical programs, progress of its myotonic dystrophy type 1 partnership, VX-670 with Vertex. The year is shaping up to have several value-driving catalysts.

I'm pleased to welcome on stage next to me, Entrada's Chief Executive Officer, Dipal Doshi, who can share more about Entrada's year ahead. And also on stage, we'll have Natarajan as well. Thank you for joining us this afternoon. I'm really pleased to hand it off to the team.

Dipal Doshi
CEO & Director

Great. Thank you. Thanks for the kind introduction and to the JPMorgan team for inviting us here to present. I look forward to talking more about the work that we're doing at Entrada.

Before I go too far, it's the normal disclaimer about making forward-looking statements. So just refer to our SEC filings

Q2: 2026-01-08 Earnings SummaryEPS of $0.10 beats by $0.03

 |

Revenue of

$224.69M

(-2.84% Y/Y)

beats by $16.32M

Neogen Corporation (NEOG) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 8:15 PM EST

Company Participants

Mikhael Nassif - CEO, President & Director

Presentation

Unknown Analyst

Good afternoon, everyone. Next up, we have Neogen, a global leader in food and animal safety providing diagnostic testing solutions used across the food supply chain and animal health markets worldwide. We're pleased to have with us Mike Nassif, President and CEO; and Bill Waelke from the IR team with us today. Over to you, team.

Mikhael Nassif
CEO, President & Director

Thank you, [ Prad ], and thank you all for being here. Before we start, I wanted to pose a question to you. Just think about your day to day. You probably grabbed something to you this morning, maybe grab something from the market to go for lunch. And maybe when you're not in a conference, you're at home buying groceries to make dinner your family or even if you have to buy baby formula. How many times do you pause and ask yourself, is this safe for me to consume before you buy it?

If you're like me, you probably never do that, right? We live under this cloak of comfort that our food is safe. And it's not trust that I think is really the opportunity that's ahead of us. The CDC -- according to the CDC, last year, there was 50 million food-borne illness cases. Of those, 100,000 were serious enough that they had to be hospitalized. And unfortunately, of those 100,000, 3,000 people lost their life to food-borne illnesses.

My name is Mike Nassif. I have the privilege of leading a company that is at the forefront of creating solutions to make sure that the food that we consume is safe. What we're going to talk about today

Myqorzo and Redemplo approved in China

Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndromeUnderscores Sanofi’s long-term commitment to China, reinforcing the ambition to provide transformative medicines to patients in disease areas with large unmet medical needs Paris, January 15, 2026. The National Medical Products Administration in China has approved two Sanofi-licensed innovative medicines, Myqorzo (aficamten) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), and Redemplo (plozasiran) for the reduction of triglyceride levels, in adult patients with familial chylomicronaemia syndrome (FCS) on the basis of dietary control.

“We are pleased to bring Myqorzo and Redemplo to patients in Greater China. Both medicines represent important advances in treatment options and address unmet medical needs among people living with complex conditions,” said Olivier Charmeil, Executive Vice President, General Medicines, Sanofi. “The latest approvals underscore Sanofi’s long-term commitment to bringing innovative medicines to Chinese patients.”

Myqorzo is a selective, small-molecule cardiac myosin inhibitor to improve functional capacity and relieve symptoms in patients with oHCM, in which the myocardium, the heart muscle, becomes abnormally thick. It is the most common monogenic inherited cardiovascular disorder. The approval was based on the positive pivotal SEQUOIA-HCM phase 3 study (clinical study identifier: NCT05186818) in patients with symptomatic oHCM.

Redemplo is a small-interfering RNA (siRNA) medicine, suppressing the production of apoc-III, an important target for reducing triglycerides in patients with FCS. FCS is a severe and rare disease where extremely high triglyceride levels can lead to various serious signs and symptoms including acute and potentially fatal pancreatitis, chronic abdominal pain, diabetes, hepatic steatosis, and cognitive issues. The approval was based on the positive pivotal PALISADE phase 3 study (clinical study identifier: NCT05089084) in patients with genetically confirmed or clinically diagnosed FCS.

About HCM
HCM is the most common inherited cardiovascular disorder, characterized by abnormal thickening of the heart muscle (myocardium). This leads to the left ventricle becoming smaller and stiffer, impairing its ability to relax and fill with blood, limiting the heart’s pumping function and exercise capacity. HCM symptoms include: chest pain, dizziness, shortness of breath, or fainting during physical activity.

HCM has two forms: oHCM (two-thirds of patients), where thickened muscle blocks blood flow, and non-obstructive HCM (one-third), where the muscle is thickened but blood flows normally.
HCM patients face serious complications including atrial fibrillation, stroke, and mitral valve disease. It's a leading cause of sudden cardiac death in young people and athletes due to dangerous heart rhythm abnormalities. Some patients have a high risk of progressive diseases leading to dilated cardiomyopathy and heart failure requiring transplantation.

About Myqorzo
Myqorzo (aficamten) is a selective, small-molecule cardiac myosin inhibitor discovered following an extensive chemical optimization program that was conducted with careful attention to therapeutic index and pharmacokinetic properties. Myqorzo was designed to reduce the number of active actin-myosin cross bridges during each cardiac cycle and consequently suppress the myocardial hypercontractility that is associated with HCM. In preclinical models, Myqorzo reduced myocardial contractility by binding directly to cardiac myosin at a distinct and selective allosteric binding site, thereby preventing myosin from entering a force producing state. Myqorzo is approved in the US and China.

Myqorzo, for the treatment of symptomatic oHCM, was designated breakthrough therapy and orphan drug in the US, and breakthrough therapy in China. On December 12, 2025, The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization in the EU with a final decision expected in the first quarter of 2026. In December 2024, Sanofi obtained exclusive rights to develop and commercialize Myqorzo in Greater China for treating both forms of HCM. These rights came through an agreement with Corxel Pharmaceuticals, who had acquired them from Cytokinetics.

About FCS
FCS is a severe and rare disease leading to extremely high triglyceride levels, over 880 mg/dL (9.94 mmol/L). Such severe elevations can lead to various serious signs and symptoms including acute and potentially fatal pancreatitis, chronic abdominal pain, diabetes, hepatic steatosis, and cognitive issues.

About Redemplo
Redemplo (plozasiran) is a siRNA medicine suppressing the production of apoC-III, a protein produced primarily in the liver that raises triglyceride levels by slowing their breakdown and clearance. By targeting apoC-III with sustained silencing, Redemplo delivers significant reductions in triglyceride levels. Redemplo has been studied in both genetically confirmed and clinically diagnosed patients living with FCS. Redemplo, for the treatment of FCS, was designated breakthrough therapy, fast track, and orphan drug in the US, orphan in the EU, and breakthrough therapy in China. Redemplo is approved in the US, Canada, and China for the treatment of FCS patients. Regulatory review is ongoing in the EU.

In August 2025, Sanofi acquired the rights to develop and commercialize Redemplo in Greater China from Visirna Therapeutics, a majority-owned subsidiary of Arrowhead Pharmaceuticals.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. 
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | [email protected]
Evan Berland | +1 215 432 0234 | [email protected]
Léo Le Bourhis | +33 6 75 06 43 81 | [email protected]
Victor Rouault | +33 6 70 93 71 40 | [email protected]
Timothy Gilbert | +1 516 521 2929 | [email protected]
Léa Ubaldi | +33 6 30 19 66 46 | [email protected]
Ekaterina Pesheva | +1 410 926 6780 | [email protected] 

Investor Relations
Thomas Kudsk Larsen | +44 7545 513 693 | [email protected]
Alizé Kaisserian | +33 6 47 04 12 11 | [email protected]
Keita Browne | +1 781 249 1766 | [email protected]
Nathalie Pham | +33 7 85 93 30 17 | [email protected]
Thibaud Châtelet | +33 6 80 80 89 90 | [email protected]
Yun Li | +33 6 84 00 90 72 | [email protected]

Sanofi forward-looking statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

All trademarks mentioned in this press release are the property of the Sanofi group.

Press Release

, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Bath & Body Works, Inc. ("Bath & Body Works " or "the Company") (NYSE: BBWI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of BBWI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: June 4, 2024 to November 19, 2025

DEADLINE: March 16, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Bath & Body Works strategy of "adjacencies, collaborations and promotions" failed to grow sales and increase customer metrics. The Company used brand collaborations to mask its poor performance. Based on these facts, Bath & Body Works' public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate .

WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT: 
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]

SOURCE DJS Law Group LLP

, /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Fermi Inc. ("Fermi " or "the Company") (NASDAQ: FRMI ) for violations of the federal securities laws.

Shareholders who purchased shares of FRMI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD:  pursuant and/or traceable to Fermi's initial public offering ("IPO") conducted in October 2025, and/or between October 1, 2025, and December 11, 2025, both dates inclusive (the "Class Period").

DEADLINE: March 6, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Fermi's "Project Matador" campus was largely depending on a funding commitment from a single potential tenant who was at risk of terminating this commitment. The Company understated the extent to which it relied on this tenant to investors. Based on these facts, Fermi's public statements were false and materially misleading throughout the IPO period.

If you are a shareholder who suffered a loss, contact us to participate .

WHY DJS LAW GROUP?  DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

 Eastchester, NY 10709

Phone: 914-206-9742

Email: [email protected]

SOURCE DJS Law Group LLP

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bath & Body Works, Inc. ("Bath & Body Works" or "the Company") (NYSE: BBWI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between June 4, 2024 and November 19, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before March 16, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Bath & Body Works' strategy of seeking "adjacencies, collaborations and promotions" failed to grow its customer base and net sales. The Company then resorted to brand collaborations to "carry quarters" despite weak financial results. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Bath & Body Works, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.          

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

Vancouver, British Columbia--(Newsfile Corp. - January 14, 2026) - Chesapeake Gold Corp. (TSXV: CKG) ("Chesapeake" or the "Company") is pleased to announce that it has filed a prospectus supplement (the "Prospectus Supplement") dated January 14, 2026, to its short form base shelf prospectus (the "Base Shelf Prospectus") dated February 23, 2024, with the securities regulatory authorities in each of the provinces and territories of Canada, other than Québec, to qualify the public distribution of 3,751,500 units of the Company (the "Units") at an offering price (the "Offering Price") of $4.20 per Unit for gross proceeds of $15,000,300 in connection with the Company's previously announced "bought deal" public Offering (the "Offering") (see news releases dated January 12, 2026).

Each Unit will consist of one common share of the Company (each, a "Common Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share at a price of $5.65 at any time on or before that date which is 36 months following the Closing Date (as defined herein).

The Offering is being made pursuant to an underwriting agreement (the "Underwriting Agreement") dated January 14, 2026 among the Company and Red Cloud Securities Inc. ("Red Cloud") as lead underwriter and joint bookrunner, and Cantor Fitzgerald Canada Corporation, joint bookrunner (together with Red Cloud, the "Underwriters").

Pursuant to the Underwriting Agreement, the Company has granted to the Underwriters an option (the "Over-Allotment Option"), exercisable in whole or in part, at any time for a period of up to 30 days after and including the Closing Date, to purchase for resale at the Offering Price up to an additional 535,725 Units of the Company (the "Over-Allotment Units") at the Offering Price to cover over-allotments, if any, and for market stabilization purposes. The Prospectus Supplement to the Base Shelf Prospectus qualifies the grant of the Over-Allotment Option and the issuance of the Over-Allotment Units pursuant thereto.

The Company has agreed to pay the Underwriters a cash fee equal to 6% of the gross proceeds of the Offering (which shall be reduced to 2% for gross proceeds from the sale of Units to certain purchasers on the president's list (the "President's List") agreed to by the Company and Red Cloud), including in respect of any gross proceeds raised on the exercise of the Over-Allotment Option. The Underwriters will also receive, on the Closing Date (as defined herein), as additional compensation, non-transferable broker warrants (the "Broker Warrants") to purchase that number of Common Shares (the "Broker Warrant Shares") equal to 6% of the aggregate number of Units issued by the Company under the Offering (including pursuant to the exercise of the Over-Allotment Option) (which shall be reduced to 2% from the sale of Units to purchasers on the President's List). Each Broker Warrant shall entitle the holder thereof to acquire one Broker Warrant Share at a price of $4.20 per Broker Warrant Share for a period of 36 months from the Closing Date.

The full particulars of the Offering along with the possible exercise and issue of Over-Allotment Units pursuant to the Over-Allotment Option are set out in the Prospectus Supplement.

The Offering is expected to close on or about January 27, 2026 (the "Closing Date"), or on such date as agreed upon between the Company and Red Cloud. The closing of the Offering is subject to the Company receiving all necessary regulatory approvals, including the final approval of the TSX Venture Exchange.

Delivery of the Base Shelf Prospectus, the Prospectus Supplement, and any amendments to such documents will be satisfied in accordance with the "access equals delivery" provisions of applicable securities legislation. The Prospectus Supplement, the Base Shelf Prospectus, and any amendment, as applicable, are accessible under the Company's profile on SEDAR+ at www.sedarplus.ca. An electronic or paper copy of the Prospectus Supplement, the Base Shelf Prospectus, and any amendment, as applicable, may be obtained, without charge, from Red Cloud Securities Inc., attention: Victoria Ellis Hayes, 120 Adelaide St. West, 14th Floor, Toronto, Ontario, M5H 1T1, email: [email protected] by providing the contact with an email address or address, as applicable.

The securities described in this news release have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any applicable securities laws of any state of the United States, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons (as such term is defined in Regulation S under the U.S. Securities Act) or persons in the United States unless registered under the U.S. Securities Act and any other applicable securities laws of the United States or an exemption from such registration requirements is available. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of these securities within any jurisdiction, including the United States, in which such offer, solicitation or sale would be unlawful.

For Further Information:

For more information on Chesapeake, its Metates and Lucy Projects or proprietary oxidative leach technology, please visit our website at www.chesapeakegold.com or contact Jean-Paul Tsotsos at [email protected] or +1 778 731 1362.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

About Chesapeake

Chesapeake Gold Corp.'s flagship asset is the Metates Project ("Metates") located in Durango State, Mexico. Metates hosts one of the largest undeveloped gold-silver deposits in the Americas1 with over 16.77 million ounces of gold at 0.57 grams per tonne (g/t) and 423.2 million ounces of silver at 14.3 g/t within 921.2 million tonnes in the Measured and Indicated Mineral Resource category and a further 2.13 million ounces of gold at 0.47 g/t and 59.0 million ounces of silver at 13.2 g/t within 139.5 million tonnes in the Inferred Mineral Resource category. See the technical report titled "Metates Sulphide Heap Leach Project Phase I" dated January 13, 2023, and news release dated February 22, 2023.

Forward-looking Statements

This news release contains "forward-looking statements" within the meaning of Canadian securities legislation. Such forward-looking statements include, without limitation, statements with respect to the Offering, the completion of the Offering and the timing in respect thereof, and the timely receipt of all necessary approvals, including the approval of the TSX Venture Exchange.

Such forward looking statements or information are based on a number of assumptions, which may prove to be incorrect. Assumptions have been made regarding, among other things: the continued advancement of the Company's technology; conditions in general economic and financial markets; the price of gold and silver; the availability and costs of mining equipment and skilled labour; accuracy of assay results; geological interpretations from drilling results; timing and amount of capital expenditures related to drilling programs; performance of available laboratory and other related services; future operating costs; and the historical basis for current estimates of potential quantities and grades of target zones, assuming the recovery of the San Vicente 3 concession on the Metates.

The actual results could differ materially from those anticipated in these forward looking statements as a result of risk factors, including the risks to development of the Company's technology, timing and content of work programs; results of exploration activities and development of mineral properties; the interpretation and uncertainties of drilling and testing results and other geological data; receipt, maintenance and security of permits and mineral property titles, including the recovery of the San Vicente 3 mineral concession; environmental and other regulatory risks; project costs overruns or unanticipated costs and expenses; availability of funds; failure to delineate potential quantities and grades of the target zones based on historical data; general market and industry conditions; changes in project parameters as plans continue to be refined; accidents, labour disputes and other risks of the mining industry; and political instability.

Forward-looking statements are based on the expectations and opinions of the Company's management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. The Company undertakes no obligation to update or revise any forward-looking statements included in this news release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law.

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

________________________
1 Mexico's biggest undeveloped gold deposits. Bnamericas, Published Tuesday, November 24, 2020.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/280470

Source: Chesapeake Gold Corp.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Shares of Trip.com Group plunged sharply on Thursday after China’s top market regulator said it had opened an antitrust investigation into the online travel services provider, triggering the company’s steepest selloff since its Hong Kong listing in 2021.

The stock fell nearly 22% in Hong Kong, making Trip.com the worst performer on the Hang Seng index for the session.

The decline followed a 17% drop in the company’s American depositary receipts overnight in New York.

The selloff put the shares on course for their worst day in Hong Kong since they were listed in April 2021.

China’s State Administration for Market Regulation (SAMR) late Wednesday said it was investigating Trip.com due to “suspected abuse of its dominant market position and monopolistic practices,” according to a CNBC translation of the statement in Mandarin.

Antitrust probe triggers sharp market reaction Copy link to section

Trip.com’s Hong Kong-listed shares were trading around 457.6 Hong Kong dollars at the time of writing, after losing roughly a fifth of their value.

Market data showed the fall erased tens of billions of Hong Kong dollars in market capitalization in a single day.

The regulator said it had begun the probe following initial investigations.

Trip.com later confirmed it had received a formal notice of investigation from SAMR and said it would “actively cooperate” with authorities, adding that its business operations were functioning as usual.

The investigation echoes previous high-profile enforcement actions against major Chinese technology firms.

In 2021, SAMR fined Alibaba Group a record 18.2 billion yuan ($2.8 billion) after it was found guilty of monopolistic practices, a case that marked a turning point in Beijing’s regulatory scrutiny of internet platforms.

Analysts flag pricing practices, potential fines Copy link to section

Analysts at Nomura said the Trip.com probe could have been prompted by concerns from hotel operators about the company’s influence over pricing.

According to Nomura, some hoteliers have complained about Trip.com’s interference in pricing and, in certain cases, its insistence on maintaining the lowest hotel-room prices compared with those offered on rival travel platforms.

Under China’s antitrust law, companies found to have abused a dominant market position can face fines of between 1% and 10% of their revenue in the previous year.

Citi analysts said this implies a potential fine of between 490 million yuan and 4.9 billion yuan, or roughly $70 million to $700 million, for Trip.com based on their calculations.

Nomura said the investigation is unlikely to fundamentally undermine Trip.com’s dominant position in China’s online travel market.

However, it could weaken the company’s influence over hotels, particularly independent operators that often rely heavily on online travel agencies for customer traffic, the bank said.

Tourism outlook remains strong despite scrutiny Copy link to section

Trip.com is the largest online travel provider in Asia by market capitalization and one of the biggest globally.

The company has stakes in UK-based flight aggregator Skyscanner, Indian travel company MakeMyTrip, and several other Chinese travel providers.

The probe comes at a time when China’s tourism sector is expected to continue its recovery and expansion.

Travel marketing and technology firm China Trading Desk estimates that mainland Chinese travelers are expected to take about 165 million to 175 million cross-border trips in 2026, up from an estimated 155 million last year.

Domestic travel has also shown steady growth.

Travel consultancy Dragon Trail International said that in 2025, 501 million Chinese traveled domestically during the Chinese New Year holiday period, a 5.9% year-on-year increase.

Tourism spending during the period reached 6.77 billion yuan, up 7%.

The upcoming Chinese New Year holiday, scheduled to be observed between Feb. 5 and Feb. 23, is expected to be another major test of travel demand, even as regulatory scrutiny adds uncertainty for the sector’s largest players.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of VET either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

PureTech Health plc (PRTC) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 7:30 PM EST

Company Participants

Robert Lyne - CEO & Director
Eric Elenko - Co-Founder & President

Conference Call Participants

Bhavana Balakrishnan

Presentation

Bhavana Balakrishnan

Good evening, everybody. Thank you so much for joining us today on day 3 of the JPMorgan Healthcare Conference. My name is Bhavana Balakrishnan. I'm an associate with the Healthcare Investment Banking team. Today, we're joined by the management of PureTech. And with us, we have Robert Lyne, Chief Executive Officer; Eric Elenko, Co-Founder and President. Over to you, Robert.

Robert Lyne
CEO & Director

Wonderful. Thank you very much, Bhavana, and thank you for everyone who's turned up today and for those who are joining on the webcast. I'm delighted to be here and thank JPMorgan for the opportunity to present to you all. So as Bhavana said, I'm Robert Lyne. I'm the CEO here at PureTech Health. I've been in the business 2 years now. I've previously held a number of senior leadership roles and CEO roles in various London-listed life science businesses and was delighted to step into the CEO role here at PureTech at the end of last year. So as we move through the presentation, there may be a number of forward-looking statements that we'll be making. I'll refer you to our SEC filings in that regard.

So as an introduction to PureTech Health, we have a proven hub-and-spoke model for drug development. So what does that mean? And how does that differentiate us from other drug development businesses? Well, what we do is we take a derisked diversified approach to developing a number of potential new therapeutic treatments for patients. We do this with a hub approach where a centralized lean, efficient hub looks at novel opportunities to develop dramatically different treatments

Google's parent was the biggest winner among the "Magnificent Seven" stocks over the last 12 months. Its momentum could continue.

For some reason, Wall Street analysts aren't excited about Google parent Alphabet (GOOG 0.04%) (GOOGL 0.04%). The consensus 12-month price target for the stock reflects a minuscule potential upside.

I don't get it. Alphabet has been the most magnificent of the so-called "Magnificent Seven" stocks over the last 12 months. All the ingredients for continued momentum appear to be in place.

Should investors believe Wall Street's uninspiring price target for Alphabet? I don't think so. Here are five reasons to buy this high-flying stock like there's no tomorrow.

Today's Change

(

-0.04

%) $

-0.13

Current Price

$

335.84

1. Alphabet remains an advertising juggernaut Advertising on Google Search, YouTube, the Google Network, and other related products continues to generate more than 72% of Alphabet's total revenue. The great news for the company is that this ad revenue is growing, jumping 12.6% year-over-year in the third quarter of 2025.

Contrary to ominous predictions after OpenAI launched ChatGPT in late 2022, generative AI has provided a catalyst for Google Search instead of being a "Google killer." Search engine traffic has increased as a result of Google's implementation of genAI integration with AI Overviews and AI Mode. GenAI products such as Imagen4 are also helping customers create more and better online ads.

2. Google Cloud's momentum seems unstoppable Generative AI has also created a massive tailwind for Google Cloud, Alphabet's cloud platform. Google Cloud remains the fastest-growing of the big three cloud service providers. The unit's revenue soared 34% year-over-year to $15.2 billion in Q3. Google Cloud's backlog increased 46% quarter-over-quarter to $155 billion.

Alphabet CEO Sundar Pichai mentioned in the Q3 earnings call that Google Cloud signed more deals of over $1 billion in the first nine months of 2025 than it did in the previous two years combined. I believe this momentum is practically unstoppable right now, especially with more organizations implementing agentic AI solutions.

3. Google Gemini is a force to be reckoned with Alphabet's large language model (LLM), Google Gemini, is the key driver behind the company's AI success thus far. I fully expect that Gemini will continue to attract customers to Google Cloud and help Google Search stay at the top, especially with the recent launch of version 3.0.

Guess what the No. 1 overall AI model is on LMArena's leaderboard? Google Gemini 3.0 Pro. And Gemini 3.0 Flash ranks third. Alphabet has thrown down the gauntlet. Google Gemini is a force to be reckoned with.

Image source: Getty Images.

4. Waymo is a rising star The robotaxi market holds the potential to be huge within the next few years. Alphabet's Waymo unit is the leader in this market.

Waymo currently offers autonomous ride-hailing services in Atlanta, Austin, Los Angeles, Phoenix, and the San Francisco area. It's planning to expand soon to 12 additional cities, including London, England.

I predict that Waymo will be worth hundreds of billions of dollars within the next few years. It's off to a good start for my prediction to be fulfilled. Alphabet is in discussions to raise an additional $15 billion or so in funding for Waymo, which would peg its valuation at up to $110 billion.

5. Alphabet has multiple other ways to grow The best stocks offer something called optionality. This term refers to the fact that they have multiple paths to growth.

Google plans to launch AI-powered glasses this year. I think that the company will be a top contender in the smart glasses market and give Meta Platforms (META 2.47%) a run for its money.

Alphabet's famous "Other Bets" could pay off in several ways. While Waymo is the most prominent member of the group, don't overlook the potential for drone delivery company Wing and healthcare technology unit Verily.

Quantum computing could also be a lottery ticket for Alphabet. Google Quantum AI has achieved two of the six milestones on its roadmap. Does Alphabet need this lottery ticket to deliver market-beating gains over the next few years? No, but quantum computing could help make the stock an even bigger winner.